3. Oral Anticoagulants in AFa,b A Brief History

4. NOACs Phase 3 Trials Spectrum of Stroke Risk in AF

5. NOACs Phase 3 Trials Dosing Strategies

6. NOACs Phase 3 Trials Mean CHADS2 Scores

7. NOACs Similar Half-Life, Different Daily Dosing?

8. NOACs in Clinical Practice Identifying Patients With Increased Bleeding Risk

9. NOACs Drug-drug Interactions

10. NOACs Monitoring Anticoagulant Effectsa

11. NOACs Considerations for Measuring Anticoagulant Activity

12. NOACs Preventing Excess Exposure

13. NOACs Antidotes and Reversal Agents

14. NOACs Antidotes and Reversal Agents (cont)

15. NOACs Addressing Patient Concernsa

16. NOACs Emerging Agents

17. Conclusions

18. Abbreviations

19. References

20. References (cont)

21. References (cont)

22. References (cont)

23. References (cont)